Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C30H50 |
| Molecular Weight | 410.718 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 4 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C=C(/C)CC\C=C(/C)CCC=C(C)C
InChI
InChIKey=YYGNTYWPHWGJRM-AAJYLUCBSA-N
InChI=1S/C30H50/c1-25(2)15-11-19-29(7)23-13-21-27(5)17-9-10-18-28(6)22-14-24-30(8)20-12-16-26(3)4/h15-18,23-24H,9-14,19-22H2,1-8H3/b27-17+,28-18+,29-23+,30-24+
| Molecular Formula | C30H50 |
| Molecular Weight | 410.718 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 4 |
| Optical Activity | NONE |
Squalene is a naturally occurring polyprenyl compound primarily known
for its key role as an intermediate in cholesterol synthesis. It received its name because of its occurrence in shark liver oil (Squalus spp.), which contains large quantities and is considered the richest source of squalene. However, it is widely distributed in nature, with reasonable
amounts found in olive oil, palm oil, wheat-germ oil, amaranth oil, and rice bran oil. The primary
therapeutic use of squalene currently is as an
adjunctive therapy in a variety of cancers. Although
epidemiological, experimental and
animal evidence suggests anti-cancer properties,
to date no human trials have been conducted
to verify the role this nutrient might
have in cancer therapy regimens.
CNS Activity
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: map00100 Sources: http://www.genome.jp/dbget-bin/www_bget?cpd:C00751 |
|||
Target ID: CHEMBL364 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20161970 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Secondary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
Doses
| Dose | Population | Adverse events |
|---|---|---|
27 g 1 times / day multiple, oral Highest studied dose Dose: 27 g, 1 times / day Route: oral Route: multiple Dose: 27 g, 1 times / day Sources: |
healthy, ADULT Health Status: healthy Age Group: ADULT Sex: F Food Status: FED Sources: |
Other AEs: Loose stools... |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Loose stools | 55% | 27 g 1 times / day multiple, oral Highest studied dose Dose: 27 g, 1 times / day Route: oral Route: multiple Dose: 27 g, 1 times / day Sources: |
healthy, ADULT Health Status: healthy Age Group: ADULT Sex: F Food Status: FED Sources: |
PubMed
| Title | Date | PubMed |
|---|---|---|
| The adjuvants aluminum hydroxide and MF59 induce monocyte and granulocyte chemoattractants and enhance monocyte differentiation toward dendritic cells. | 2008-04-15 |
|
| Benzopyrans, biphenyls and xanthones from the root of Garcinia linii and their activity against Mycobacterium tuberculosis. | 2006-04 |
|
| Two new sesquiterpenoids and anti-HIV principles from the root bark of Zanthoxylum ailanthoides. | 2005-11-01 |
|
| Effect of squalene on tissue defense system in isoproterenol-induced myocardial infarction in rats. | 2004-09 |
|
| Simvastatin modulates expression of the PON1 gene and increases serum paraoxonase: a role for sterol regulatory element-binding protein-2. | 2003-11-01 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17313043
The efficacy of diets with different contents of squalene (100, 200, 400, 600 mg per day) was compared. It was shown that antiatherosclerotic diet with inclusion 600 mg squalene has promoted the most positive changes of immune status. The consumption of 200-400 mg of squalene per day produced the more significant antioxidant effect.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/14602142
Squalene (12.5-25 uM) treatment significantly protected the CFUs (human bone marrow (BM) derived colony-forming unit) from cisplatin-induced toxicity
| Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Apr 02 18:26:59 GMT 2025
by
admin
on
Wed Apr 02 18:26:59 GMT 2025
|
| Record UNII |
7QWM220FJH
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C860
Created by
admin on Wed Apr 02 18:26:59 GMT 2025 , Edited by admin on Wed Apr 02 18:26:59 GMT 2025
|
||
|
LOINC |
79326-5
Created by
admin on Wed Apr 02 18:26:59 GMT 2025 , Edited by admin on Wed Apr 02 18:26:59 GMT 2025
|
||
|
DSLD |
1853 (Number of products:19)
Created by
admin on Wed Apr 02 18:26:59 GMT 2025 , Edited by admin on Wed Apr 02 18:26:59 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
m10166
Created by
admin on Wed Apr 02 18:26:59 GMT 2025 , Edited by admin on Wed Apr 02 18:26:59 GMT 2025
|
PRIMARY | Merck Index | ||
|
100000091876
Created by
admin on Wed Apr 02 18:26:59 GMT 2025 , Edited by admin on Wed Apr 02 18:26:59 GMT 2025
|
PRIMARY | |||
|
638072
Created by
admin on Wed Apr 02 18:26:59 GMT 2025 , Edited by admin on Wed Apr 02 18:26:59 GMT 2025
|
PRIMARY | |||
|
D013185
Created by
admin on Wed Apr 02 18:26:59 GMT 2025 , Edited by admin on Wed Apr 02 18:26:59 GMT 2025
|
PRIMARY | |||
|
C77219
Created by
admin on Wed Apr 02 18:26:59 GMT 2025 , Edited by admin on Wed Apr 02 18:26:59 GMT 2025
|
PRIMARY | |||
|
7QWM220FJH
Created by
admin on Wed Apr 02 18:26:59 GMT 2025 , Edited by admin on Wed Apr 02 18:26:59 GMT 2025
|
PRIMARY | |||
|
10014
Created by
admin on Wed Apr 02 18:26:59 GMT 2025 , Edited by admin on Wed Apr 02 18:26:59 GMT 2025
|
ALTERNATIVE | |||
|
SUB25541
Created by
admin on Wed Apr 02 18:26:59 GMT 2025 , Edited by admin on Wed Apr 02 18:26:59 GMT 2025
|
PRIMARY | |||
|
111-02-4
Created by
admin on Wed Apr 02 18:26:59 GMT 2025 , Edited by admin on Wed Apr 02 18:26:59 GMT 2025
|
PRIMARY | |||
|
SQUALENE
Created by
admin on Wed Apr 02 18:26:59 GMT 2025 , Edited by admin on Wed Apr 02 18:26:59 GMT 2025
|
PRIMARY | |||
|
8242
Created by
admin on Wed Apr 02 18:26:59 GMT 2025 , Edited by admin on Wed Apr 02 18:26:59 GMT 2025
|
PRIMARY | |||
|
15440
Created by
admin on Wed Apr 02 18:26:59 GMT 2025 , Edited by admin on Wed Apr 02 18:26:59 GMT 2025
|
PRIMARY | |||
|
253201
Created by
admin on Wed Apr 02 18:26:59 GMT 2025 , Edited by admin on Wed Apr 02 18:26:59 GMT 2025
|
PRIMARY | |||
|
7QWM220FJH
Created by
admin on Wed Apr 02 18:26:59 GMT 2025 , Edited by admin on Wed Apr 02 18:26:59 GMT 2025
|
PRIMARY | |||
|
DTXSID0026044
Created by
admin on Wed Apr 02 18:26:59 GMT 2025 , Edited by admin on Wed Apr 02 18:26:59 GMT 2025
|
PRIMARY | |||
|
203-826-1
Created by
admin on Wed Apr 02 18:26:59 GMT 2025 , Edited by admin on Wed Apr 02 18:26:59 GMT 2025
|
PRIMARY | |||
|
DB11460
Created by
admin on Wed Apr 02 18:26:59 GMT 2025 , Edited by admin on Wed Apr 02 18:26:59 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PARENT -> CONSTITUENT ALWAYS PRESENT | |||
|
PARENT -> CONSTITUENT ALWAYS PRESENT |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PARENT -> METABOLITE |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |